Evidence
Curr Cardiol Rep. 2024 Feb 20. doi: 10.1007/s11886-024-02025-6. Online ahead of print.
ABSTRACT
PURPOSE OF REVIEW: The objective of this manuscript is to examine the current literature on the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD), its correlation with cardiovascular disease (CVD) outcomes, as well as to evaluate the update in nomenclature from non-alcoholic liver disease (NAFLD).
RECENT FINDINGS: The update of diagnostic criteria from NAFLD to MASLD reduces the stigma associated with alcohol consumption and poor health choices. It also shines a light on the crucial role of cardiometabolic risk factors in disease pathophysiology. The incidence and prevalence of MASLD are projected to increase significantly in the future as the population burden of cardiometabolic risk factors rises. MASLD is also a potent risk factor for developing CVD that should be tackled by using a multi-disciplinary team with a holistic approach. As the new nomenclature for metabolic liver disease is adopted on a global scale, more research is needed to investigate the applicability of findings from previous trials focusing on NAFLD. It is anticipated that the epidemic of MASLD will continue to increase globally, hence the urgent need for therapeutic approaches to reverse this trend.
PMID:38376745 | DOI:10.1007/s11886-024-02025-6
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
The Global Epidemic of Metabolic Fatty Liver Disease
🌐 90 Days
VR Related Evidence Matrix
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Metabolic disease and the liver: A review
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- Metabolic Muddle. MASLD and MASH on the Horizon
- Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Occult liver disease: a multinational perspective
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- A narrative review about cognitive impairment in Metabolic Dysfunction-Associated Liver Disease (MASLD): Another matter to face through a holistic approach
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- COVID-19 in Individuals with Chronic Liver Diseases
- The role of Sirtuin 2 in liver - An extensive and complex biological process
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
- Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS
- Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- The association of Neuromedin U levels and non-alcoholic fatty liver disease: A comparative analysis
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation
- Liver Biopsy Handling of Metabolic-Associated Fatty Liver Disease (MAFLD): the Children's Hospital of Eastern Ontario grossing protocol
- Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study
- TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
- Therapeutic potential of oleanolic acid in liver diseases
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
Evidence Blueprint
The Global Epidemic of Metabolic Fatty Liver Disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
The Global Epidemic of Metabolic Fatty Liver Disease
🌐 365 Days
VR Related Evidence Matrix
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
- Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
- Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
- Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
- Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings
- Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
- From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
- The double roles of T cell-mediated immune response in the progression of MASLD
- Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease: A State-of-the-Art Review
- Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions
- Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults
- National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature
- Adipose-derived extracellular vesicles - a novel cross-talk mechanism in insulin resistance, non-alcoholic fatty liver disease, and polycystic ovary syndrome
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Update in lean metabolic dysfunction-associated steatotic liver disease
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- MELD-Na score may underestimate disease severity and risk of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
- Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease
- Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function
- A multi-society Delphi consensus statement on new fatty liver disease nomenclature
- Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease
- Fatty liver disease's renaming impacts on drug clinical trials
- Metabolic disease and the liver: A review
- Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
- Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population
- The pathophysiology of MASLD: an immunometabolic perspective
- Gut commensal Kineothrix alysoides mitigates liver dysfunction by restoring lipid metabolism and gut microbial balance
- Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease
- Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD)
- Metabolic Muddle. MASLD and MASH on the Horizon
- Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
- Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks
- Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022)
- Impacts of Non-alcoholic Fatty Liver Disease on Acute Coronary Syndrome: Evidence and Controversies
- Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients
- Metabolic-dysfunction associated steatotic liver disease-related diseases, cognition and dementia: A two-sample mendelian randomization study
- Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Occult liver disease: a multinational perspective
- Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
- Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
- Corrected and republished from: Metabolic associated liver disease
- Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the…
- MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease
- Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis